Kalderos FAQ

Who should I reach out to if I have questions about Kalderos tools and solutions?





You can access our Help Center 24/7 for assistance in using the Kalderos Platform of Tools and Solutions. If you need additional help, we provide comprehensive Technical and User Support via phone at 844-930-2322 and email via support@kalderos.com, Monday through Friday from 8am CST to 8pm CST. During non-business hours we also provide limited phone and email User Support to walk you through using the Kalderos Platform of Tools and Solutions. If you have a technical issue and we are unable to assist you during this time, we will report your request to our Support team and someone will be able to follow up with you during normal business hours.

Visit Help Center

Who is Kalderos?





Kalderos is a technology company focused on building trust, transparency and equity across the healthcare system. We work with all stakeholders - providers, payers, manufacturers and patients - to ensure the right discount to the right party on the right transaction℠.

Learn more

What does Kalderos do?





Kalderos provides unifying technologies that bring transparency, trust and equity to the entire healthcare community. Our first-of-its-kind Drug Discount Management solution ensures that drug discount programs work on behalf of patients.

Who does Kalderos work with?





Kalderos is proud to partner with manufacturers, payers, providers and others, including government agencies, to ensure drug discount programs work as intended.

What problems does Kalderos solve?





We are on a mission to solve systemic problems of the healthcare system, leading off with noncompliance in drug discount programs. This noncompliance totaled nearly $8.5 billion in 2018.

What is the Drug Discount Management platform?





After years of observing noncompliance in drug discount programs, Kalderos is launching the Drug Discount Management platform to establish the infrastructure that allows discounts to be validated and paid accurately the first time. The Drug Discount Management platform is the infrastructure that all our products are built on to protect the long-term viability of drug discount programs and to ensure that patients can afford the medications they need.

What security protocols does Kalderos’ Drug Discount Management platform use?





For more information, click below to download a detailed document.

Read information security overview

How do I know if a manufacturer uses Kalderos’ Drug Discount Management platform?





Kalderos maintains a list of products for which Kalderos is the 340B discount effectuator. Please follow the link below to see the list.

See product list

What does Kalderos do to address privacy/HIPAA concerns?





For more information, click "Learn More" below to download a detailed document.

Read additional HIPAA FAQ

What are the Kalderos tools available to manufacturers?





Kalderos currently offers two tools for manufacturers. The first, Verify, is part of the 340B Pay solution, and is a secure and intuitive tool designed to enable manufacturers to work with thousands of providers to facilitate the exchange of drug discounts on a single platform. The second, Review, is an easy-to-use tool that allows manufacturers to work with 340B covered entities in “good faith” to validate suspected duplicate discounts.

Kalderos for drug manufactuers

What are the benefits of a manufacturer choosing Kalderos?





Kalderos delivers a multifaceted, collaborative approach to drug discount effectuation for manufacturers. The “Verify” and “Review” tools include a monitoring control to identify past instances of noncompliance and a preventative control to stop revenue leakage now and in the future, ensuring the right discount to the right party on the right transaction®

Can Kalderos interface with contract pharmacies?





Yes, Kalderos can support a covered entity’s contract pharmacy relationship(s). For drugs dispensed at contract pharmacies, through 340B Pay, the 340B discount will be realized in the form of a rebate after compliance is confirmed.

What is the justification for permissibility of 340B rebates?





The Pharmaceutical Pricing Agreement (PPA) that is signed by manufacturers of covered outpatient drugs participating in the 340B program (and MDRP) does not prohibit rebates or mandate any mechanism for ensuring that 340B covered entities do not pay more than the statutory 340B ceiling price. As such, the legal status quo is that rebates are permissible as a mechanism to achieve appropriate prices for covered drugs purchased by covered entities under 340B. Furthermore, HRSA's own guidance supports the conclusion that the status quo permits use of the rebate mechanism. See e.g., Notice Regarding Section 602 of the Veterans Healthcare Act of 1992 - Rebate Option, Health Resources and Services Administration, 63 Fed. Reg. 35239 (June 29, 2998). Under that guidance, voluntary rebate agreements with covered entities that provide at least the minimum statutory discount and do not contain requirements inconsistent with section 340B and published program guidelines are considered consistent with the section 340B rebate program. Id at 35240. Under this guidance, rebates are currently in use (with the Secretary's approval) by State AIDS Drug Assistance Programs (ADAPs).

How do you ensure the solution meets the needs of all stakeholders in the 340B ecosystem?





Kalderos has actively engaged representatives from all facets of the 340B ecosystem. Please see the blog posts below outlining our efforts to engage all stakeholders in our platform pilots.

How do the Kalderos tools integrate with our current systems, either revenue management, managed services, or both?





Kalderos can interface with your existing systems/partners to ensure seamless and compliant transfer of data in accordance with our security and control environment. Please see the illustrations below for additional information.

What are the contracting implications of partnering with Kalderos?





Kalderos does not require any updated contract terms with any of your existing partners. Updates to any existing contracts remain at the discretion of you, the manufacturer.

Can Kalderos actively support 340B price restatements?





Kalderos can provide full visibility into the 340B discount extended by a participating drug manufacturer to a covered entity. Kalderos maintains up to date, quarterly based pricing enabling all parties to have transparency for determining accurate pricing based on changes to a previously calculated 340B price.

How can we ensure compliance with security and control protocols?





Please see Kalderos’ Information Security overview for more information on the security and controls environment in place to ensure compliance.

Read information security overview

How can we learn more about Kalderos’ offerings?





Kalderos maintains a large library of resources related to our Drug Discount Management platform and our solutions.

Visit library

How do we get in touch with a representative from Kalderos?





Kalderos has a team of experts available to assist all stakeholders. They can be reached at support@kalderos.com.

What are the Kalderos tools available to providers?





Kalderos currently offers two tools for providers. The first, Request, is part of the 340B Pay solution, and is a secure and intuitive tool designed to enable providers to request compliant drug discounts at the point of sale. The second, Review, is an easy-to-use tool that allows manufacturers to work with 340B covered entities in “good faith” to validate suspected duplicate discounts.

Kalderos for providers

What benefits will covered entities realize by being able to decide between the upfront discount or the receipt of the rebate directly?





Covered entities now have an option to determine which process is best for them. For those covered entities that wish to use the current model of inventory replenishment, they will need to participate in using Review for the good faith inquiry process. At their contract pharmacies, covered entities will see a decrease in resources to maintain oversight, simplification of their auditable records and no impact on cash flow. Uninsured patients will be able to receive their discounts at the contract pharmacy.

How will partnering with Kalderos impact the relationship I have with my contract pharmacies and 340B Administrators (TPAs)?





Kalderos’ program will allow the capture and processing of all prescription transactions from the covered entity’s pharmacy network. Kalderos places no restrictions on the 340B network of contract pharmacies a covered entity has. 340B administrators will still apply the covered entity’s eligibility to the transactions. Contract pharmacies will receive a negotiated fee for their services. 340B Administrators (TPAs) will continue to apply the covered entity eligibility rules to the transactions as they have done in the past. With 340B Pay, instead of tracking the inventory and ordering through the wholesaler, they will send the eligible claims with the units dispensed to Kalderos. TPAs will be paid for their services by the covered entity based on their contractual agreement

What is the justification for permissibility of rebates?





Will we need to change our 340B Administrator to provide Kalderos with the needed information?





Kalderos has created a platform that can accept the minimum amount of information from the covered entity, the pharmacy or the 340B Administrator. You will not be asked to switch your vendor.

What are the contracting requirements for covered entities to ensure receipt of the appropriate discount from the manufacturer?





Covered entities will need to enter into an agreement with the manufacturer and a third-party payment platform, allowing the rebate from the manufacturer to be electronically deposited into their bank account. The contracting process is done within the Kalderos platform.

If a mistake has been found in any of the rebate payments, how will adjustments be made?





Kalderos’ mission is to ensure the right discount to the right party on the right transaction®. This includes ensuring that a “post-audit” mechanism is in place to validate that not only was a duplicate discount not paid, but that the appropriate rebate was paid. Kalderos will work with manufacturers and covered entities to correct any discrepancies found within the platform.

Control & security environment





Please see Kalderos’ Information Security overview for more information on the security and controls environment in place to ensure compliance.

Read information security overview

How will Kalderos protect the patient’s private information?





Kalderos takes the protection of sensitive information very seriously. Please see the below FAQ related to the measures that Kalderos takes to protect all health information.

Read HIPAA FAQ

Does Kalderos require a business associates agreement?





No. Kalderos works with stakeholders throughout the pharmaceutical supply chain on behalf of drug manufacturers that provide the 340B discount. Healthcare providers that are ‘covered entities’ under HIPAA can disclose information covered by HIPAA consistent with HIPAA for their own payment purposes without a BAA as part of their payment activities, among other purposes. See 45 C.F.R sec 164.501.

How can we learn more about Kalderos’ offerings?





Kalderos maintains a large library of resources related to our Drug Discount Management platform and our solutions

Visit library

How do we get in touch with a representative from Kalderos to learn more?





Kalderos has a team of experts available to assist all stakeholders. They can be reached at support@kalderos.com

What is the 340B Pay solution?





Kalderos’ 340B Pay solution includes everything needed to assess, coordinate and approve 340B rebates. It includes the covered entity tool, Request, and the manufacturer tool, Verify. Together, these two tools allow covered entities and manufacturers to facilitate 340B discounts, make adjustments to previously-submitted discount requests, and provide state Medicaid agencies with the information needed for the state to avoid asking the manufacturer for a Medicaid rebate on a dispensing record subject to a 340B discount. Using sophisticated models and machine learning processes, Kalderos detects inconsistencies overlooked by current methods, providing material benefits by eliminating waste. With Kalderos’ 340B Pay solution, all manufacturer and covered entity funds flow directly through a third-party payment provider and its financial institution partner(s), and not Kalderos, to efficiently and quickly pay and receive 340B discounts.

Learn more about 340B Pay

How does the Kalderos Discount Monitoring solution work?





Kalderos works with state agencies and drug manufacturers to gather claims data through the Verify tool. Kalderos analyzes claims data and by leveraging proprietary datasets, machine learning and algorithms, determines which claims have a high likelihood of being non-compliant. When necessary, Kalderos works with providers through the Review tool to confirm which claims are 340B duplicate discounts. Kalderos works with manufacturers and state agencies to resolve non-compliant discounts.

Learn more about Discount Monitoring

Answers to all your questions.

Our support team is here to help

Additional helpful resources

Looking for product support? We’re here to help.